Editing Pfizer (section)

== Areas of focus == 

Pfizer focuses on addressing critical health challenges through innovation in various therapeutic areas. In the field of rare diseases, the company develops treatments for conditions such as [[Duchenne muscular dystrophy]], [[Haemophilia|hemophilia]], [[sickle cell disease]], and [[Gaucher's disease|Gaucher disease]], with an inclination on [[gene therapy]] and improving diagnostic resources for patients with unmet medical needs.<ref>{{cite web |title=Pfizer gene therapy research delayed by trial changes, safety questions |author=Ned Pagliarulo|url=https://www.biopharmadive.com/news/pfizer-gene-therapy-delay-dmd-hemophilia/609390/ |date=3 November 2021|website=BioPharma Dive |access-date=26 March 2025}}</ref>

=== Internal medicine ===

Pfizer has a longstanding history in vaccines, contributing to breakthroughs in diseases like polio and smallpox. Currently, the company focuses on vaccines for pneumococcal and meningococcal diseases, influenza, respiratory syncytial virus (RSV), [[Lyme disease]], and [[Clostridioides difficile]].<ref>{{cite web |title=Pfizer reports durable second-season efficacy for RSV vaccine |author=Lisa Schnirring|date=29 February 2024|url=https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/pfizer-reports-durable-second-season-efficacy-rsv-vaccine |website=[[Center for Infectious Disease Research & Policy]] |access-date=27 March 2025}}</ref><ref>{{cite web |title=Lyme Disease Vaccine Reaches Completion of the Primary Series
|url=https://www.contagionlive.com/view/lyme-disease-vaccine-reaches-completion-of-the-primary-series |author=John Parkinson|date=19 July 2024|website=Contagion |access-date=27 March 2025}}</ref> It also invests in maternal and neonatal vaccines, [[cancer prevention]], and efforts to mitigate [[Hospital-acquired infection|hospital-acquired infections]]. It also works in advancing therapies for issues related to metabolic and cardiovascular health, including obesity, [[type 2 diabetes]], [[insulin resistance]], and non-alcoholic fatty liver disease (NAFLD).<ref>{{cite web |title=CDC Endorses Pfizer’s Maternal RSV Vaccine to Shield Newborns |url=https://respiratory-therapy.com/products-treatment/pharmaceuticals/us-pharmaceuticals/cdc-endorses-pfizers-maternal-rsv-vaccine-shield-newborns/ |website=Respiratory Therapy|date=26 September 2023|access-date=27 March 2025}}</ref>

=== Obesity Treatment Developments === 

Pfizer has advanced its obesity treatment research through the development of [[danuglipron]], an oral [[glucagon-like peptide-1]] (GLP-1) receptor agonist:<ref name="techtarget">{{cite web |title=Pfizer advances daily oral GLP-1 research |url=https://www.techtarget.com/pharmalifesciences/news/366606009/Pfizer-advances-daily-oral-GLP-1-research|author=Veronica Salib |website=TechTarget |date=12 July 2024|access-date=29 March 2025}}</ref>

* '''Danuglipron Development''': Initial trials of the twice-daily formulation showed potential for weight loss and blood sugar management. 

* '''New Formulation''': A once-daily modified-release version has been identified for further study, showing a suitable pharmacokinetic profile and no significant safety issues in trials involving 1,400 participants.

Dose optimization trials are planned for late 2024 to support large-scale registration studies.<ref name="techtarget"/>

=== Oncology === 

Pfizer develops targeted therapies to treat multiple cancer types, including bladder, breast, cervical, lung, and colorectal cancers, as well as hematological malignancies. The company conducts research on [[Personalized medicine|precision medicine]] and [[immunotherapy]], aiming to improve survival rates and quality of life for cancer patients. Specially, the acquisition of Seagen has supported further development of oncology treatments, including mRNA cancer vaccines.<ref name="Driving equitable">{{cite web |title=Elif Aral: Driving equitable healthcare in the region |url=https://www.arabianbusiness.com/resources/elif-aral-driving-equitable-healthcare-in-the-region |date=22 October 2024|website=[[Arabian Business]] |access-date=30 March 2025}}</ref>

* '''Prostate Cancer''': The EMBARK trial showed improved metastasis-free survival in high-risk, non-metastatic prostate cancer patients, leading to the FDA approval of a combination therapy in 2023.<ref>{{cite web |title=Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer |author=Stephen J. Freedland, M.D., Murilo de Almeida Luz, M.D., Ugo De Giorgi, M.D., Ph.D., Martin Gleave, M.D., Geoffrey T. Gotto, M.D., M.P.H., Christopher M. Pieczonka, M.D., Gabriel P. Haas, M.D., Choung-Soo Kim, M.D., Miguel Ramirez-Backhaus, M.D., Antti Rannikko, M.D., Ph.D., Jamal Tarazi, M.D., M.P.A., Swetha Sridharan, M.B., B.S., Jennifer Sugg, M.S., Yiyun Tang, Ph.D., Ronald F. Tutrone, Jr., M.D., Balaji Venugopal, M.B., B.S., M.D., Arnauld Villers, M.D., Ph.D., Henry H. Woo, M.B., B.S., D.Med.Sc., Fabian Zohren, M.D., Ph.D., and Neal D. Shore, M.D. |url=https://www.nejm.org/doi/full/10.1056/NEJMoa2303974 |website=[[The New England Journal of Medicine]] |date=2023-10-18 |access-date=2025-03-30 |doi=10.1056/NEJMoa2303974}}</ref>

* '''The TALAPRO-2''' study explored treatments for metastatic prostate cancer with homologous recombination repair mutations, which are found in 25% of cases.<ref>{{cite web |title=Clinical Trials + Font Resize - Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC |url=https://www.pharmabiz.com/NewsDetails.aspx?aid=172947&sid=2 |website=Pharmabiz.com |date=11 October 2024|access-date=30 March 2025}}</ref>

* '''Bladder Cancer:''' The EV-302 study investigated new treatments for advanced urothelial cancer, focusing on improving care for hard-to-treat patient groups.<ref>{{cite web |title=PADCEV® (Enfortumab Vedotin-ejfv) with KEYTRUDA® (Pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer |url=https://www.urotoday.com/ev-302-te/articles.html?id=148585 |website=UroToday |access-date=30 March 2025}}</ref>

===Advances in AI, Gene Therapy, and Breakthrough Treatments=== 

Pfizer has also started initiatives which aim to address healthcare challenges across various regions and therapeutic areas in advancements in artificial intelligence (AI), gene therapy, obesity treatments, and oncology research. In 2023, Pfizer’s affordability and access programs reached 45 million patients in the MERA region, supported by the IUdo app, which was launched in [[Egypt]], [[Qatar]], and [[Lebanon]] to facilitate patient access to care. In 2024, Pfizer focuses on integrating AI and gene therapy in the [[Middle East]], [[Russia]], and [[Africa]] (MERA) region, with its headquarters in [[Dubai]].<ref name="Driving equitable"/> Key initiatives include:
* '''Personalized Healthcare''': Omnichannel strategies are being used to provide tailored healthcare solutions for patients and professionals.<ref>{{cite web |title=Omnichannel Engagement in Pharma: Process and Challenges |url=https://medicaldigitals.com/blogs/pharmaceutical-marketing/omnichannel-engagement-pharma/ |date=24 January 2024|website=Medical Digitals |access-date=6 April 2025}}</ref>
* '''AI-Powered Education Programs:''' AI-driven atrial fibrillation programs localized educational materials into multiple languages, increasing accessibility. 
* '''Rare Disease Research:''' Collaboration with the Abu Dhabi Department of Health to analyze real-world data on Sickle Cell Disease using AI.<ref>{{cite web |title=Department of Health – Abu Dhabi Partners with Pfizer to Advance Research in Sickle Cell Disease and Beyond |url=https://www.doh.gov.ae/en/news/doh-partners-with-pfizer-to-advance-research-in-sickle-cell-disease-and-beyond |website=Department of Health Abu Dhabi|date=4 June 2024|access-date=6 April 2025}}</ref>